Clinical trials
Withdrawn Leukemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 41 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Emory University | 2 |
| M.D. Anderson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Rush University Medical Center | 2 |
| University of New Mexico | 2 |
| AbbVie | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Altor BioScience | 1 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| Astex Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 41 |
| Lymphoma | 16 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 |
| Leukemia, Myeloid, Acute | 10 |
| Lymphoma, Non-Hodgkin | 6 |
| Myelodysplastic Syndromes | 6 |
| Congenital Abnormalities | 5 |
| Lymphoma, B-Cell, Marginal Zone | 5 |
| Lymphoma, Follicular | 5 |
Trials
Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.